nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—Feeling abnormal—Cisplatin—bone cancer	0.00184	0.00184	CcSEcCtD
Anagrelide—Weight increased—Epirubicin—bone cancer	0.00184	0.00184	CcSEcCtD
Anagrelide—Haematuria—Methotrexate—bone cancer	0.00183	0.00183	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Anagrelide—Weight decreased—Epirubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Anagrelide—Hepatobiliary disease—Methotrexate—bone cancer	0.00182	0.00182	CcSEcCtD
Anagrelide—Epistaxis—Methotrexate—bone cancer	0.00181	0.00181	CcSEcCtD
Anagrelide—Pneumonia—Epirubicin—bone cancer	0.00181	0.00181	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—bone cancer	0.0018	0.0018	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—bone cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Renal failure—Epirubicin—bone cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Body temperature increased—Cisplatin—bone cancer	0.00177	0.00177	CcSEcCtD
Anagrelide—Conjunctivitis—Epirubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Anagrelide—Urinary tract infection—Epirubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Anagrelide—Haemoglobin—Methotrexate—bone cancer	0.00174	0.00174	CcSEcCtD
Anagrelide—Haemorrhage—Methotrexate—bone cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Hepatitis—Methotrexate—bone cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Sweating—Epirubicin—bone cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—bone cancer	0.00173	0.00173	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—bone cancer	0.00172	0.00172	CcSEcCtD
Anagrelide—Pharyngitis—Methotrexate—bone cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Urinary tract disorder—Methotrexate—bone cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—bone cancer	0.00171	0.00171	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—bone cancer	0.0017	0.0017	CcSEcCtD
Anagrelide—Urethral disorder—Methotrexate—bone cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—bone cancer	0.00168	0.00168	CcSEcCtD
Anagrelide—Visual impairment—Methotrexate—bone cancer	0.00166	0.00166	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—bone cancer	0.00164	0.00164	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—bone cancer	0.00162	0.00162	CcSEcCtD
Anagrelide—Eye disorder—Methotrexate—bone cancer	0.00161	0.00161	CcSEcCtD
Anagrelide—Tinnitus—Methotrexate—bone cancer	0.00161	0.00161	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—bone cancer	0.00161	0.00161	CcSEcCtD
Anagrelide—Asthenia—Cisplatin—bone cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—bone cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Cardiac disorder—Methotrexate—bone cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—bone cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—bone cancer	0.0016	0.0016	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—bone cancer	0.00159	0.00159	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Anagrelide—Mediastinal disorder—Methotrexate—bone cancer	0.00156	0.00156	CcSEcCtD
Anagrelide—Chills—Methotrexate—bone cancer	0.00155	0.00155	CcSEcCtD
Anagrelide—Diarrhoea—Cisplatin—bone cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Alopecia—Methotrexate—bone cancer	0.00153	0.00153	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Anagrelide—Malnutrition—Methotrexate—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—bone cancer	0.00149	0.00149	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—bone cancer	0.00146	0.00146	CcSEcCtD
Anagrelide—Back pain—Methotrexate—bone cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Chills—Epirubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—bone cancer	0.00143	0.00143	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—bone cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Vision blurred—Methotrexate—bone cancer	0.00142	0.00142	CcSEcCtD
Anagrelide—Rash—Cisplatin—bone cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Dermatitis—Cisplatin—bone cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—bone cancer	0.00141	0.00141	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—bone cancer	0.0014	0.0014	CcSEcCtD
Anagrelide—Ill-defined disorder—Methotrexate—bone cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Anaemia—Methotrexate—bone cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Anagrelide—Tension—Epirubicin—bone cancer	0.00138	0.00138	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—bone cancer	0.00137	0.00137	CcSEcCtD
Anagrelide—Back pain—Epirubicin—bone cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Malaise—Methotrexate—bone cancer	0.00136	0.00136	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—bone cancer	0.00135	0.00135	CcSEcCtD
Anagrelide—Chills—Doxorubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—bone cancer	0.00134	0.00134	CcSEcCtD
Anagrelide—Nausea—Cisplatin—bone cancer	0.00133	0.00133	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—bone cancer	0.00133	0.00133	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—bone cancer	0.00132	0.00132	CcSEcCtD
Anagrelide—Cough—Methotrexate—bone cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—bone cancer	0.00131	0.00131	CcSEcCtD
Anagrelide—Convulsion—Methotrexate—bone cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—bone cancer	0.0013	0.0013	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—bone cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Arthralgia—Methotrexate—bone cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Chest pain—Methotrexate—bone cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Myalgia—Methotrexate—bone cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Tension—Doxorubicin—bone cancer	0.00128	0.00128	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Malaise—Epirubicin—bone cancer	0.00127	0.00127	CcSEcCtD
Anagrelide—Discomfort—Methotrexate—bone cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Syncope—Epirubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—bone cancer	0.00126	0.00126	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—bone cancer	0.00125	0.00125	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Anagrelide—Confusional state—Methotrexate—bone cancer	0.00124	0.00124	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Anagrelide—Cough—Epirubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Infection—Methotrexate—bone cancer	0.00122	0.00122	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Anagrelide—Nervous system disorder—Methotrexate—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Thrombocytopenia—Methotrexate—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Anagrelide—Skin disorder—Methotrexate—bone cancer	0.00119	0.00119	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Anagrelide—Hyperhidrosis—Methotrexate—bone cancer	0.00119	0.00119	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Anorexia—Methotrexate—bone cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Oedema—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Hypotension—Methotrexate—bone cancer	0.00115	0.00115	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Infection—Epirubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Cough—Doxorubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Anagrelide—Shock—Epirubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—bone cancer	0.00112	0.00112	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Insomnia—Methotrexate—bone cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Anagrelide—Paraesthesia—Methotrexate—bone cancer	0.0011	0.0011	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Anagrelide—Dyspnoea—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Anagrelide—Somnolence—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Dyspepsia—Methotrexate—bone cancer	0.00108	0.00108	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Decreased appetite—Methotrexate—bone cancer	0.00107	0.00107	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Methotrexate—bone cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Fatigue—Methotrexate—bone cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Infection—Doxorubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Anagrelide—Pain—Methotrexate—bone cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Shock—Doxorubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Anagrelide—Feeling abnormal—Methotrexate—bone cancer	0.00101	0.00101	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Anagrelide—Gastrointestinal pain—Methotrexate—bone cancer	0.001	0.001	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—bone cancer	0.000998	0.000998	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—bone cancer	0.000993	0.000993	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000991	0.000991	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—bone cancer	0.00099	0.00099	CcSEcCtD
Anagrelide—Pain—Epirubicin—bone cancer	0.000982	0.000982	CcSEcCtD
Anagrelide—Constipation—Epirubicin—bone cancer	0.000982	0.000982	CcSEcCtD
Anagrelide—Urticaria—Methotrexate—bone cancer	0.000975	0.000975	CcSEcCtD
Anagrelide—Body temperature increased—Methotrexate—bone cancer	0.00097	0.00097	CcSEcCtD
Anagrelide—Abdominal pain—Methotrexate—bone cancer	0.00097	0.00097	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000968	0.000968	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—bone cancer	0.000961	0.000961	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—bone cancer	0.000954	0.000954	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—bone cancer	0.000947	0.000947	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—bone cancer	0.000946	0.000946	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—bone cancer	0.000944	0.000944	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—bone cancer	0.000939	0.000939	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—bone cancer	0.000935	0.000935	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—bone cancer	0.000923	0.000923	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000917	0.000917	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—bone cancer	0.000916	0.000916	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—bone cancer	0.000912	0.000912	CcSEcCtD
Anagrelide—Pain—Doxorubicin—bone cancer	0.000908	0.000908	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—bone cancer	0.000908	0.000908	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—bone cancer	0.000908	0.000908	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—bone cancer	0.000908	0.000908	CcSEcCtD
Anagrelide—Asthenia—Methotrexate—bone cancer	0.00088	0.00088	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—bone cancer	0.000875	0.000875	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000869	0.000869	CcSEcCtD
Anagrelide—Pruritus—Methotrexate—bone cancer	0.000868	0.000868	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—bone cancer	0.000844	0.000844	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—bone cancer	0.00084	0.00084	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—bone cancer	0.00084	0.00084	CcSEcCtD
Anagrelide—Diarrhoea—Methotrexate—bone cancer	0.000839	0.000839	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—bone cancer	0.000824	0.000824	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—bone cancer	0.000812	0.000812	CcSEcCtD
Anagrelide—Dizziness—Methotrexate—bone cancer	0.000811	0.000811	CcSEcCtD
Anagrelide—Diarrhoea—Epirubicin—bone cancer	0.000785	0.000785	CcSEcCtD
Anagrelide—Vomiting—Methotrexate—bone cancer	0.00078	0.00078	CcSEcCtD
Anagrelide—Rash—Methotrexate—bone cancer	0.000773	0.000773	CcSEcCtD
Anagrelide—Dermatitis—Methotrexate—bone cancer	0.000773	0.000773	CcSEcCtD
Anagrelide—Headache—Methotrexate—bone cancer	0.000769	0.000769	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—bone cancer	0.000762	0.000762	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—bone cancer	0.000759	0.000759	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—bone cancer	0.000752	0.000752	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—bone cancer	0.00073	0.00073	CcSEcCtD
Anagrelide—Nausea—Methotrexate—bone cancer	0.000729	0.000729	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—bone cancer	0.000727	0.000727	CcSEcCtD
Anagrelide—Rash—Epirubicin—bone cancer	0.000724	0.000724	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—bone cancer	0.000723	0.000723	CcSEcCtD
Anagrelide—Headache—Epirubicin—bone cancer	0.000719	0.000719	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—bone cancer	0.000702	0.000702	CcSEcCtD
Anagrelide—Nausea—Epirubicin—bone cancer	0.000682	0.000682	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—bone cancer	0.000675	0.000675	CcSEcCtD
Anagrelide—Rash—Doxorubicin—bone cancer	0.00067	0.00067	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—bone cancer	0.000669	0.000669	CcSEcCtD
Anagrelide—Headache—Doxorubicin—bone cancer	0.000665	0.000665	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—bone cancer	0.000631	0.000631	CcSEcCtD
